Corcept Therapeutics (NASDAQ: CORT) reported Q4 EPS of $0.14, $0.10 worse than the analyst estimate of $0.24. Revenue for the quarter came in at $103.1 million versus the consensus estimate of $105.08 million.

For earnings history and earnings-related data on Corcept Therapeutics (CORT) click here.